We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Equivalence of Pegfilgrastim and Filgrastim in Lymphoma Patients Treated with BEAM Followed by Autologous Stem Cell Transplantation.
- Authors
Samaras, Panagiotis; Buset, Elefteri M.; Siciliano, Raffaele Daniele; Haile, Sarah R.; Petrausch, Ulf; Mischo, Axel; Honegger, Hanspeter; Pestalozzi, Bernhard C.; Schanz, Urs; Stussi, Georg; Stahel, Rolf A.; Knuth, Alexander; Renner, Christoph; Stenner-Liewen, Frank
- Abstract
Objective: To evaluate the impact of pegfilgrastim on engraftment, hospital stay and resources in patients with Hodgkin's and non-Hodgkin's lymphoma after conditioning with high-dose BEAM followed by autologous peripheral blood stem cell transplantation (APBSCT) compared with filgrastim. Methods: We reviewed patient charts and our prospective transplantation database for clinical data from the post-transplant period. An integrated cost analysis, including the use of blood products and length of hospital stay, was also performed. Results: Fourteen (26%) patients with Hodgkin's lymphoma and 40 (74%) patients with non-Hodgkin's lymphoma were analyzed. Thirty-four (68%) patients received single-dose pegfilgrastim (6 mg), and 20 (32%) patients received daily filgrastim (5 μg/kg) after APBSCT. No differences were observed regarding duration of neutropenia grade 4 (pegfilgrastim median 7 days/filgrastim median 8 days; p = 0.13), thrombocytopenia grade 4 (7/9.5 days, respectively; p = 0.21), fever (4.5/2 days; p = 0.057), intravenous antibiotic treatment (11/10 days; p = 0.75) or length of hospital stay (16.5/16 days; p = 0.27) between the groups. The use of pegfilgrastim resulted in 12% higher treatment-related costs when compared to filgrastim, without reaching statistical significance (p = 0.38). Conclusion: Pegfilgrastim appears to be equivalent to filgrastim after high-dose BEAM followed by APBSCT in the treatment of lymphoma patients. Copyright © 2010 S. Karger AG, Basel
- Subjects
FILGRASTIM; HODGKIN'S disease; STEM cell transplantation; COST analysis; LYMPHOMA treatment; THERAPEUTICS
- Publication
Oncology, 2010, Vol 79, Issue 1/2, p93
- ISSN
0030-2414
- Publication type
Article
- DOI
10.1159/000320604